Wells Fargo initiated coverage on Alphatec with a new price target
$ATEC
Medical/Dental Instruments
Health Care
Wells Fargo initiated coverage of Alphatec with a rating of Overweight and set a new price target of $26.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/1/2024 | Overweight → Equal-Weight | Morgan Stanley | |
| 7/8/2024 | $19.00 | Overweight | Barclays |
| 2/9/2024 | $26.00 | Overweight | Wells Fargo |
| 12/19/2023 | $16.00 → $18.00 | Buy | Needham |
| 10/20/2023 | $22.00 | Buy | ROTH MKM |
| 10/12/2022 | $12.00 | Buy | Jefferies |
| 9/12/2022 | $13.00 | Overweight | Morgan Stanley |
| 3/2/2022 | $22.00 → $17.00 | Overweight | Piper Sandler |
8-K - Alphatec Holdings, Inc. (0001350653) (Filer)
8-K - Alphatec Holdings, Inc. (0001350653) (Filer)
144 - Alphatec Holdings, Inc. (0001350653) (Subject)
Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced the pricing of its offering of $350,000,000 aggregate principal amount of 0.75% convertible senior notes due 2030 (the "notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The offering size was increased from the previously announced offering size of $300,000,000 aggregate principal amount of notes. The issuance and sale of the notes are scheduled to settle on March 7, 2025, subject to customary closing conditions. ATEC also granted the initi
Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced its intention to offer, subject to market and other conditions, $300,000,000 aggregate principal amount of convertible senior notes due 2030 (the "notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). ATEC also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $50,000,000 principal amount of notes.
Full year 2024 total revenue grew 27% to $612 million, enabling significant profit margin expansion Full year 2025 total revenue expected to approximate $732 million and fuel free cash flow Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced financial results for the quarter and year ended December 31, 2024, and business highlights. Fourth Quarter and Full Year 2024 Financial Results Quarter Ended December 31, 2024 Year Ended December 31, 2024 Total revenue $177 million $612 million GAAP gross margin 69% 69% Non-GAAP gross marg
4 - Alphatec Holdings, Inc. (0001350653) (Issuer)
4 - Alphatec Holdings, Inc. (0001350653) (Issuer)
4 - Alphatec Holdings, Inc. (0001350653) (Issuer)
Morgan Stanley downgraded Alphatec from Overweight to Equal-Weight
Barclays initiated coverage of Alphatec with a rating of Overweight and set a new price target of $19.00
Wells Fargo initiated coverage of Alphatec with a rating of Overweight and set a new price target of $26.00
Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will report third quarter 2024 financial results on October 30, 2024, after the market close. The Company will host a live webcast that day at 1:30 p.m. PT / 4:30 p.m. ET. Webcast To access the live webcast, please visit the Investor Relations Section of ATEC's Corporate Website. Dial-in To dial into the live webcast, please register at this link. Access details will be shared via email. Replay A replay of the webcast will remain available through the Investor Relations Section of ATEC's Corporate Website for twelve months. Indu
Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will report second quarter 2024 financial results on July 31, 2024, after the market close. The Company will host a live webcast that day at 1:30 p.m. PT / 4:30 p.m. ET. Webcast To access the live webcast, please visit the Investor Relations Section of ATEC's Corporate Website. Dial-in To dial into the live webcast, please register at this link. Access details will be shared via email. Replay A replay of the webcast will remain available through the Investor Relations Section of ATEC's Corporate Website for twelve months.
Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will report first quarter 2024 financial results on May 7, 2024, after the market close. The Company will host a live webcast that day at 1:30 p.m. PT / 4:30 p.m. ET. Webcast To access the live webcast, please visit the Investor Relations Section of ATEC's Corporate Website. Dial-in To dial into the live webcast, please register at this link. Access details will be shared via email. Replay A replay of the webcast will remain available through the Investor Relations Section of ATEC's Corporate Website for twelve months. In
SC 13D/A - Alphatec Holdings, Inc. (0001350653) (Subject)
SC 13D/A - Alphatec Holdings, Inc. (0001350653) (Subject)
SC 13D/A - Alphatec Holdings, Inc. (0001350653) (Subject)
4 - Alphatec Holdings, Inc. (0001350653) (Issuer)
4 - Alphatec Holdings, Inc. (0001350653) (Issuer)
4 - Alphatec Holdings, Inc. (0001350653) (Issuer)
Paragon 28, Inc. (NYSE:FNA), (the "Company") a leader in foot and ankle surgical solutions, today announced the appointment of Dave Demski to serve as an independent director of the Company, effective immediately. Mr. Demski brings a wealth of global orthopedic expertise, with over two decades of executive leadership experience. With the addition of Mr. Demski, the Company increased the size of its Board of Directors from eight members to nine members and has further strengthened its strategic oversight and governance capabilities. Mr. Demski most recently served as the President and CEO of Globus Medical from August 2017 to April 2022, guiding the organization through a period of signifi
Spineology Inc. ("Spineology" or the "Company"), the leader in ultra-minimally invasive spine surgery, announced today the addition of Emory Rooney as Executive Vice President, Sales. In this role, Rooney will lead U.S. market growth and sales efforts. Rooney comes to Spineology with extensive spine sales experience, having served in Medical Device fields related to spinal implants and navigation for nearly 20 years. "The addition of Emory adds even further conviction about our clear opportunity for growth at Spineology," said Brian Snider, Chief Executive Officer at Spineology. "I have had the opportunity to work with Emory and have seen his impact leading sales teams, building new terri
Brian Snider Appointed New CEO Spineology Inc. ("Spineology" or the "Company"), the leader in ultra-minimally invasive spine surgery, announced today that John Booth will retire from his role as Chief Executive Officer of Spineology, effective November 10, 2023. The Board of Directors has selected Brian Snider as its next Chief Executive Officer, effective November 13, 2023. Mr. Booth will remain with Spineology through 2024, serving in an advisory role to facilitate a smooth transition. Mr. Booth will also resign from the Board of Directors, and the Board has nominated Mr. Snider as a Director. Snider joins Spineology with nearly twenty years of progressive leadership experience in the